JanOnes Innovative Approach to Addressing Chronic Pain Filing International Patent Application for Low Dose Naltrexone
28 June 2023
On June 28, 2023, JanOne made a significant move by filing an international patent application for innovative methods involving the utilization of low dose naltrexone to effectively address chronic pain. This groundbreaking development showcases JanOne’s dedication to finding novel solutions for complex regional pain syndrome (CRPS), an orphan disease that currently lacks FDA-approved treatments.
Low-dose naltrexone (LDN) has emerged as a prominent treatment option for various conditions such as fibromyalgia, CRPS, and painful diabetic neuropathy. The potential of LDN extends beyond chronic pain, as studies have indicated its promise in mitigating autoimmune disorders and even combating certain cancers. However, further research is required to fully ascertain its efficacy in treating these conditions.